Disclaimer: This article is for informational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition.
Overview
This section identifies the active ingredient in Ozempic and its related pharmaceutical counterparts available in Canada.
Ozempic is a brand-name medication containing the active substance semaglutide. In the Canadian pharmaceutical market, semaglutide is also available under the brand name Rybelsus (an oral tablet) and Wegovy (a higher-dose injectable). While these products share the same active ingredient, they are approved for distinct therapeutic uses and follow different administration schedules.
Ozempic is available in Canada as a liquid solution within pre-filled, multi-dose injection pens.
The medication is distributed in several pen strengths to allow for different dosing schedules:
- 0.25 mg or 0.5 mg per dose (1.34 mg/mL pen)
- 1 mg per dose (1.34 mg/mL or 4 mg/3 mL pen)
- 2 mg per dose (8 mg/3 mL pen)
How Ozempic Works
Ozempic works by mimicking a natural hormone that regulates various metabolic functions within the body.
At a biological level, semaglutide acts as a GLP-1 receptor agonist. It mimics the "glucagon-like peptide-1" hormone produced in the gut. By binding to specific receptors, it stimulates the release of insulin when needed, reduces the production of extra sugar by the liver, and slows down the rate at which food leaves the stomach.
Dosage Instructions of Ozempic
Administration involves a once-weekly subcutaneous injection following strict safety and hygiene protocols.
Ozempic is intended for subcutaneous injection (under the skin) once every seven days. It is typically injected into the abdomen, thigh, or upper arm. Users should rotate injection sites with each dose and should never share their pen with others, even if the needle is changed, to prevent the spread of infection.
Storage Instructions
Proper temperature control is essential to maintain the stability and effectiveness of the semaglutide molecule. Before first use: Store in the refrigerator between 2°C to 8°C. Do not freeze. After first use: The pen can be stored at room temperature (up to 30°C) or in the refrigerator for up to 56 days. Protection: Keep the pen cap on when not in use to protect the medication from light.
Side Effects of Ozempic
Users may experience digestive changes, though more serious physiological reactions require immediate medical attention.
Common Side Effects:
- Nausea and vomiting
- Diarrhea or constipation
- Abdominal pain and bloating
Serious Side Effects:
- Pancreatitis: Severe pain in the abdomen that does not go away.
- Gallbladder problems: Fever and pain in the upper stomach.
- Vision changes: Rapid changes in visual clarity.
- Hypoglycemia: Critically low blood sugar levels.
Important Safety Information About Ozempic
Health Canada provides specific warnings regarding family medical history and the potential for serious organ-related issues.
Health Canada has noted that semaglutide may be associated with a risk of thyroid C-cell tumours. It is generally not recommended for individuals with a personal or family history of Medullary Thyroid Carcinoma (MTC). Additionally, patients with a history of kidney issues or severe gastrointestinal disease should be monitored closely by a doctor.
Drug Interactions
Certain medications, especially those affecting digestion or blood sugar, can interact with Ozempic.
Because Ozempic slows stomach emptying, it can affect how the body absorbs oral medications taken at the same time. It may also interact with:
- Other GLP-1 receptor agonists.
- Insulin or insulin-stimulating medications (increasing the risk of low blood sugar).
- Certain herbal supplements that influence metabolic rates.
Brands & DIN Number of Ozempic
Brand Names
- Ozempic (for type 2 diabetes)
- Wegovy (for chronic weight management - separate indication)
- Rybelsus (oral formulation - semaglutide tablets)
DIN (Drug Identification Numbers)
02471469
Key Takeaways
- 1Ozempic (semaglutide) is a GLP-1 receptor agonist approved by Health Canada for type 2 diabetes management
- 2Mechanism: Stimulates insulin release, suppresses glucagon, slows gastric emptying, and reduces appetite
- 3Dosing: Starts at 0.5 mg once weekly, titrated to 1-2 mg weekly based on response
- 4 Common Side Effects: Nausea, vomiting, diarrhea (usually temporary and diminish over time)
- 5Serious Risks: Pancreatitis, thyroid concerns, severe hypoglycemia (especially with insulin)
- 6Contraindications: Personal/family history of medullary thyroid carcinoma or MEN 2 syndrome
- 7Drug Interactions: Increases hypoglycemia risk with insulin and sulfonylureas; affects oral contraceptive absorption
- 8Storage: Refrigerate at 2-8°C; can be kept at room temperature for up to 28 days after first use
- 9Prescription Required: Available only by prescription in Canada; not available OTC
- 10 Cardiovascular Benefits: Reduces risk of major adverse cardiovascular events in patients with established heart disease
- 11